DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13616
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJindal, Anil B.-
dc.date.accessioned2024-01-03T04:45:20Z-
dc.date.available2024-01-03T04:45:20Z-
dc.date.issued2022-
dc.identifier.urihttps://www.ingentaconnect.com/content/ben/cdt/2022/00000023/00000009/art00004-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13616-
dc.description.abstractThe commensal microbiota is known to regulate host physiology. Dysbiosis or compromised resilience in the microbial ecology is related to the impending risk of cancer. A potential link between cancer and microbiota is indicated by a lot of evidence. The current review explores in detail the various links leading to and /or facilitating oncogenesis, providing sound reasoning or a basis for its utilization as potential therapeutic targets. The present review emphasizes the existing knowledge of the microbiome in cancer and further elaborates on the factors, like genetic modifications, effects of dietary components, and environmental agents, that are considered to assess the direct and indirect effect of microbes in the process of oncogenesis and on the host’s health. Strategies modulating the microbiome and novel biotherapeutics are also discussed. Pharmacomicrobiomics is one such niche accounting for the interplay between the microbiome, xenobiotic, and host responses, which is also looked upon. The literature search strategy for this review was conducted by following the methodology of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). The method includes the collection of data from different search engines, like PubMed, ScienceDirect, SciFinder, etc., to get coverage of relevant literature for accumulating appropriate information regarding microbiome, cancer, and their linkages.en_US
dc.language.isoenen_US
dc.publisherBentham Scienceen_US
dc.subjectPharmacyen_US
dc.subjectGut microbiotaen_US
dc.subjectCanceren_US
dc.subjectMicrobiomeen_US
dc.subjectMicrobiome-based treatmenten_US
dc.subjectPharmacomicrobiomicsen_US
dc.subjectTargeted modulationen_US
dc.titleBugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatmenten_US
dc.typeArticleen_US
Appears in Collections:Department of Pharmacy

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.